SEC Filing Summary: Revelation Biosciences, Inc. (REVB)
Business Context and Reporting Period
This Form 8-K Current Report, dated December 3, 2025, covers the results of a Special Meeting of Stockholders held by Revelation Biosciences, Inc. The filing primarily addresses the approval of share issuances related to Class I Common Stock Warrants and the establishment of a fixed expiration date for these warrants.
Key Financial Metrics
The filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance actions and voting results.
Material Changes and Voting Results
Stockholders approved two key proposals at the Special Meeting, where a quorum was established by 2,460,527 shares (representing greater than one-third of the 5,924,137 shares outstanding and entitled to vote).
- Proposal 1 (Warrant Authorization): Approved the reservation and issuance of common stock pursuant to Class I Common Stock Warrants dated September 11, 2025, to the extent issuances may exceed 20% of total outstanding shares (triggering the Exchange Cap).
- For: 2,347,650
- Against: 109,808
- Abstain: 3,069
- Proposal 2 (Adjournment Authority): Approved discretionary authority to adjourn the Special Meeting if insufficient proxies were present to approve the issuance of shares in excess of the Exchange Cap.
- For: 2,377,129
- Against: 82,853
- Abstain: 545
As a result of the stockholder approval, the expiration date of the Class I Common Stock Warrants is now fixed at December 3, 2030.
Management Commentary and Other Information
Following the meeting, CEO James Rolke provided a corporate update regarding recent progress and product developments. A transcript of this update is included as Exhibit 99.1. The filing explicitly states that the information in Item 8.01 and Exhibit 99.1 is furnished and not "filed" for purposes of Section 18 of the Exchange Act, nor is it subject to the liabilities of that section.
Investor Verification Checklist
- Verify the terms of the Class I Common Stock Warrants dated September 11, 2025, including the exercise price and the specific mechanics of the Exchange Cap.
- Review the definitive proxy statement filed on November 10, 2025, for detailed descriptions of the proposals.
- Examine Exhibit 99.1 (Transcript of Corporate Update) for specific details on product developments, noting that this information is not legally "filed" under the Exchange Act.
- Confirm the current total outstanding share count to assess the potential dilution impact of the warrant issuances exceeding the 20% threshold.